GlassScriptPhysician profile
Kamman Chan
NPI 1073766259
$3,333.83
in general payments reported to CMS, 2019-2025
18 companies · $662 in 2025
The $662 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,195 · 2022: $195 · 2023: $641 · 2024: $641 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.47 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $517.92 | 2021-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $451.50 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $399.73 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $328.40 | 2021-2025 | Lifevest |
| Amgen INC. | $137.84 | 2021-2024 | Repatha |
| Abbott Laboratories | $131.93 | 2021-2024 | Mitraclip |
| Chiesi USA, INC. | $129.30 | 2021-2024 | Kengreal |
| Pfizer INC. | $106.03 | 2023-2025 | |
| Terumo Medical Corporation | $94.43 | 2021 | |
| Alnylam Pharmaceuticals INC. | $85.68 | 2025 | Amvuttra |
| Abiomed | $73.15 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $68.63 | 2024-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $44.83 | 2024 | Symplicity G3, Onyx Frontier |
| Edwards Lifesciences Corporation | $39.63 | 2025 | Sapien 3 Ultra Resilia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $38.04 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $18.34 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $17.98 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamman Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.